PLR 9

Drug Profile

PLR 9

Latest Information Update: 02 Feb 2007

Price : $50

At a glance

  • Originator Essential Therapeutics [CEASED]; PLIVA d.d.
  • Class Antibacterials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 24 Oct 2006 PLIVA d.d. has been acquired by Barr Pharmaceuticals
  • 04 Oct 2004 Essential Therapeutics has closed down
  • 12 Mar 2004 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top